bullish•CRISPR Therapeutics AG•24 May 2023 18:33
CRISPR Therapeutics AG (CRSP US): First Genome Editing Based Drug Candidate Seeking FDA Approval
CRISPR completed regulatory submissions for exa-cel (world’s first CRISPR gene editing drug) in US and awaits FDA action date. Exa-cel has the...
bullish•Vertex Pharmaceuticals•22 Dec 2022 15:05
Vertex Pharmaceuticals (VRTX US): A High-Quality Deep Pocket Biotech Must-Have for Every Investor
By leveraging on industry-leading profitability, strong balance sheet and current cash flow, Trikafta, Vertex is re-investing in next-generation...
bullish•Vertex Pharmaceuticals•05 Aug 2022 18:50
Vertex Pharmaceuticals (VRTX US): Beat-And-Raise Q2 Results Driven by Strong Uptake of Trikafta
Vertex’s strong Q2 results and 2022 guidance raise enhance our conviction on its CF leadership position. The company is also advancing its pipeline...
bullish•Sana Biotechnology Inc•27 Jan 2021 23:24
Sana Biotechnology IPO. Moving The Genomic Revolution Forward
We expect strong investor demand for upcoming IPO of Sana Biotechnology, disruptor in novel engineered cell therapies to treat cancer, diabetes,...
bearish•S&P 500 INDEX•20 May 2020 07:34